Hikma Pharma guides for injectables growth after profit surge
The Jordan-based, Hikma Pharma said its core operating profit rose to $460 million for the year ended Dec. 31 from $386 million a year earlier.
New Delhi: Hikma Pharmaceuticals Plc on Wednesday reported a 19 per cent rise in full-year core operating profit, helped by strong demand for its injectable drugs and a rebound in its generics business.
The Jordan-based drugmaker said its core operating profit rose to $460 million for the year ended Dec. 31 from $386 million a year earlier.
Also Read: Hikma wins right to market Roche drug copy in Middle East and North Africa
Core revenue rose 7 per cent to $2.08 billion, with Hikma's injectables business accounting for about 40 per cent of the total.
Hikma Pharmaceuticals is a multinational pharmaceutical company with headquarters in London, UK that manufactures non-branded generic and in-licensed pharmaceutical products.
It was founded in Amman, Jordan in 1978 by Samih Darwazah. It is listed on the London Stock Exchange and is a constituent of the FTSE 100 Index.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd